Trooperstocks
2日前
$MAJI NEWS: NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth
NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth
Exousia Pro, Inc.
Wed, June 17, 2026 at 7:00 AM EDT 4 min read
BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.
At the center of this unified ecosystem are the company's three primary operational drivers: Chairman of the Advisory Board Dr. Marvin Hausman, MD; world-renowned neuroscientist and inventor Dr. Kimi Sugaya; and healthcare entrepreneur Casey Barksdale. Together, this leadership trio bridges the critical gap that historically stalls biotech companies by connecting brilliant scientific discovery directly to an established, high-volume commercial pipeline.
The Innovation Meets Distribution Ecosystem
While many medical technology companies spend years raising dilutive capital while waiting for a breakthrough product, NexTel is executing a dual-track strategy. The company has integrated its recent acquisitions, JumpstartRx and NueVistraMed, to establish an immediate, non-dilutive, foundational revenue stream that is currently generating $135,000 to $140,000 per month.
Crucially, these segments form a turnkey healthcare infrastructure. Through the extensive industry relationships and networks built by Casey Barksdale, NexTel has secured a massive, proprietary distribution channel that eliminates traditional barriers to market entry. This single sales channel boasts an extraordinary commercial footprint:
Active Patient Reach: Interacted with over 300,000 active patients just last month alone.
Rapid Expansion: Currently onboarding 5,000 new patients per day.
Facility Network: Encompasses more than 1,500 online clinics and over 350 physical medical facilities.
This unprecedented distribution outlet provides Dr. Hausman and Dr. Sugaya with an immediate, built-in audience for all viable medical products and diagnostic tools developed by the company.
Driving the Home Runs: Advanced Diagnostic Pipeline
This powerful sales funnel is perfectly timed to support the commercial launch of NexTel's flagship medical technology: the Nanog Cancer Screening Test. Invented by Dr. Sugaya and backed by a fully granted, protected underlying patent (US 11,193,174 issued on December 7, 2021), the Nanog platform utilizes saliva samples rather than invasive blood draws to isolate and analyze exosomes—tiny cellular particles—to detect cancer-related signals at an ultra-early stage, long before traditional methods can identify a tumor's physical presence.
Dr. Hausman's extensive decades of experience as a surgeon, clinical researcher, and successful corporate entrepreneur (having previously founded Medco Research, which ultimately became part of Pfizer) is driving the clinical and regulatory pathway for the Nanog platform. Institutional Review Board (IRB) clinical testing is slated to begin shortly to validate earlier results, with management targeting an aggressive commercial launch timeline as early as September or October 2026.
The Revenue Engine: From Singles to Home Runs
By combining steady operational "singles and doubles" with high-impact scientific "home runs," NexTel is breaking the mold of standard biotechnology. Every component of the company is designed to feed into the next. In addition to its current telehealth and diagnostic initiatives, NexTel is advancing a high-volume prescription-fulfillment program. Once fully operational, this program is projected to process approximately 2,000 prescriptions per day at an estimated $4 per prescription, layering an additional, highly predictable revenue stream onto the platform.
"What we are building at NexTel is a complete healthcare ecosystem," said Matt Dwyer, CEO of NexTel Medical. "We aren't asking our shareholders to wait years for a single moonshot technology to clear regulatory hurdles before seeing commercial traction. We have operational segments generating revenue today, a revolutionary diagnostic technology entering clinical validation, and a massive distribution channel adding 5,000 patients a day to receive these products. Dr. Hausman, Dr. Sugaya, and Casey Barksdale have brought the pieces together to make NexTel a formidable force in modern healthcare."
About NexTel Medical Corp.
NexTel Medical Corp. (OTC Pink: MAJI) is a pioneering biotechnology leader and diversified healthcare platform at the forefront of exosome research, clinical diagnostics, and wellness accessibility. The Company specializes in developing proprietary, next-generation, exosome-based delivery systems and non-invasive screening tools—including its flagship Maxasome™ line—utilizing proprietary filtration and stabilization techniques to deliver high-purity solutions for personalized medicine. By combining these disruptive medical technologies with immediate, recurring-revenue operations from its strategic acquisitions of JumpstartRx and NueVistraMed, NexTel has built a comprehensive healthcare infrastructure. Serving a rapidly expanding nationwide network of over 1,850 online and brick-and-mortar clinics, NexTel uniquely bridges the gap between complex biotechnology innovation and direct clinical application, accelerating its commercial product pipeline while driving long-term shareholder value.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve substantial risks and uncertainties, including completion of clinical testing, regulatory approvals, operational execution, and market acceptance of new products. Actual results could differ materially from those projected or implied in the forward-looking statements.
Contact:
NexTel Medical Corp.
info@nextelmedical.com
www.nextelmedical.com
X: @NexTelMedical
https://finance.yahoo.com/healthcare/articles/nextel-medical-outlines-revenue-model-110000058.html via
@Yahoo @NexTelMedical
#Medical #Sales #Revenue #Growth
Trooperstocks
1週前
$MAJI News: NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University
June 09, 2026 07:00 ET | Source: Exousia Pro, Inc.
Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.
ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.
The pioneering study utilizes state-of-the-art mass spectrometry to map and isolate the exact bioactive compounds responsible for the therapeutic and healing properties within NexTel's proprietary mushroom-derived exosomes. The research specifically targets and measures critical therapeutic compounds, including Beta-glucans, Polyphenols, and Terpenoids, among others. According to Dr. Marvin Hausman, Chairman of NexTel's Scientific Advisory Board, NexTel is believed to be the first company in the world to conduct this level of sophisticated molecular analysis on mushroom exosomes.
Mass spectrometry is a high-tech lab technique that allows scientists to take a tiny sample of a substance and instantly determine three things: exactly what it is, how much of it there is, and how its individual pieces are put together.
The profound commercial implications of these preliminary findings have already initiated the drafting of new intellectual property and patent filings. Full comprehensive results from the Penn State study are anticipated by the end of June 2026. Fully decoding the molecular blueprint of these exosomes will accelerate NexTel's product pipeline, fueling highly targeted formulations for the company's rapidly expanding telehealth platform, and potentially opening massive distribution channels in the high-growth functional cosmetic and skincare space.
Executive Commentary
"We are incredibly fortunate to have assembled a world-class Scientific Advisory Board with such deep, specialized expertise in mycology and clinical research," said Matt Dwyer, President and CEO of NexTel Medical Corp. "The ability to execute this landmark study at Penn State alongside Dr. Bitzer was made possible through the strategic vision of our SAB Chairman, Dr. Hausman. Dr. Hausman has built an advisory council that unlocks proprietary insights completely unknown to the rest of the industry. Unlocking the true 'healing code' of these exosomes gives us an extraordinary competitive advantage, translating directly into valuable new patents, disruptive product lines, and advanced future clinical testing."
Our Chairman of the Scientific Advisory Board Stated
"This study represents a paradigm shift in how we understand natural cellular communication using plant-based nutrients. Mass spectrometry (MS) is an analytical tool used to measure the mass-to-charge ratio of molecules and accurately identify the compounds in the exosomes produced by our technology. The mushroom is a key food dating back to early humans and contains key bioactive compounds that play a role in physiologic processes such as inflammation, memory, and anti-aging," added Dr. Marvin S. Hausman, MD, Chairman of the Scientific Advisory Board.
About NexTel Medical Corp.
NexTel Medical Corp. is a pioneering biotechnology company at the intersection of clinical innovation and patient access. The company specializes in developing proprietary, next-generation exosome-based delivery systems designed to maximize the bioavailability and therapeutic efficacy of bioactive compounds. Through its integrated telehealth division, NexTel is dedicated to streamlining the commercialization pipeline, delivering cutting-edge, clinically backed wellness and longevity therapies directly to patients.
Forward-Looking Statements: This press release contains forward-looking statements regarding the development and commercialization of NexTel Medical Corp's products. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
NexTel Medical Corp.
info@nextelmedical.com
www.nextelmedical.com
X: @NexTelMedical
Trooperstocks
2週前
$MAJI NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders.
ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: JumpstartRx and NueVistraMed.
The strategic acquisitions immediately inject $135,000 per month in baseline revenue into NexTel’s portfolio, with substantial near-term revenue expansion anticipated as several high-margin clinical initiatives come online later this year.
Transaction Details and Financial Structure Under the terms of the definitive agreements, NexTel will acquire both entities for a total consideration of $8 million, consisting of $2 million in cash and $6 million in preferred stock. The transaction is structured to align performance with long-term shareholder value, featuring a $1 million performance-based bonus upon the achievement of specific revenue projections, alongside structured claw-back provisions if designated operational benchmarks are not achieved. [Supplemental Information filed June 2, 2026].
Significantly, NexTel intends to utilize proceeds from its LMMY shares to fund the transaction. Consequently, there will be no share dilution to existing $MAJI stockholders. The final closing of the transaction is anticipated to take place within 60 to 75 days, subject to the delivery of audited financial statements for both JumpstartRx and NueVistraMed.
Strategic Synergy & Revenue Growth Drivers The current combined baseline revenue of $135,000 per month represents highly scalable future revenue streams poised for immediate integration, including recurring high-margin injectables and nationwide testosterone prescriptions across all associated clinics, which generate a baseline of an anticipated $4.00 per script.
Furthermore, this transaction serves as a massive operational launchpad for NexTel's upcoming proprietary product line, Maxasome™. The combined platforms bring an established distribution network consisting of more than 1,500 online clinics and 350 brick-and-mortar medical facilities, providing an instant, highly receptive commercial channel for NexTel's patent-protected and patent-pending exosome technologies.
Executive Commentary
"We are thrilled to officially welcome JumpstartRx, NueVistraMed, and their visionary founder, Casey Barksdale, to the NexTel family," said Matt Dwyer, President of NexTel Medical Corp. "Casey and his team will be instrumental drivers of our expansion into the multi-billion-dollar wellness industry. Crucially, their existing infrastructure will directly propel the commercial rollout of Maxasome™. Casey has already provided invaluable insights into novel clinical applications for exosomes. Together, we have formulated a product line that we believe vastly outperforms current market alternatives, and his team is uniquely positioned to maximize its commercial adoption."
Casey Barksdale, Founder of JumpstartRx and NueVistraMed, added:
"As an organization deeply committed to clinical excellence, patient outcomes, and medicine affordability, this merger represents an extraordinary milestone. Joining forces with NexTel allows us to execute a highly consolidated, aggressive effort to bring next-generation diagnostic tests and therapies to market through diversified distribution channels. Our unified goal is clear: empower providers to detect health issues earlier through advanced screening, and leverage our robust pharmaceutical partnerships to enhance patient quality of life and longevity."
Portfolio Company Overviews
About JumpstartRx (www.Jumpstartrx.com) JumpstartRx is an innovative, direct-to-consumer telehealth platform tailored to integrate seamlessly with large organizations, enterprise employers, and affinity groups. The platform provides members with streamlined, cost-effective access to essential wellness medications, optimizing workforce health while directly enhancing the corporate bottom line. JumpstartRx differentiates itself by delivering cutting-edge medicine delivery systems and sustainable pharmaceutical discounts for everyday families.
About NueVistraMed (www.NuevistraMed.com) NueVistraMed is a comprehensive, institutional ecosystem for medical clinics, empowering healthcare providers with immense collective buying power. The company provides over 1,850 combined digital and physical clinics with priority access to leading wellness pharmaceuticals, medical supplies, proprietary credit card processing, and integrated employee benefits. Committed to improving patient outcomes, keeping pace with medical technology, and enhancing clinical profitability, NueVistraMed provides partners with patent-pending delivery systems designed for rapid absorption and superior bioavailability. The company also maintains a strategic manufacturing agreement with a prominent 503B compounding facility to produce highly affordable, accessible testosterone therapies.
About NexTel Medical Corp.
NexTel Medical Corp. (OTCPK: MAJI) is a pioneering biotechnology leader at the forefront of exosome research, clinical diagnostics, and wellness accessibility. The Company specializes in developing proprietary, next-generation, exosome-based delivery systems and non-invasive screening tools designed to revolutionize both therapeutic and diagnostic modalities. By leveraging proprietary filtration and stabilization techniques, NexTel provides high-purity, additive-free solutions for the future of personalized medicine.
Following its strategic acquisitions of JumpstartRx and NueVistraMed, NexTel’s rapidly expanding telehealth and clinical solutions division bridges the gap between complex biotechnology innovation and direct clinical application. Serving a network of over 1,850 online and brick-and-mortar clinics nationwide, NexTel is uniquely positioned to accelerate the launch of its commercial product pipeline, including its flagship Maxasome™ line, while driving immediate revenue growth and long-term shareholder value.
Forward-Looking Statements: This press release contains forward-looking statements regarding the development and commercialization of NexTel Medical Corp’s products. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
NexTel Medical Corp.
info@nextelmedical.com
www.nextelmedical.com
X: @NexTelMedical
https://www.globenewswire.com/newsroom/ti?nf=OTczMDU3OCM3NjMyOTQyIzUwMDE1ODM1Mg==
https://ml.globenewswire.com/media/MDJkMDRkNDctNDIxZi00YjNiLTk3YWMtMDc2ODBlZjNmODE0LTUwMDE1ODM1Mi0yMDI2LTA2LTAyLWVu/tiny/Exousia-Pro-Inc-.png
Source: Exousia Pro, Inc.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
JJZander
2週前
Cassius Longinus
3月前
i_like_bb_stock
4月前
Ecomike
4月前
Golden Cross
5月前
メールアドレスで登録
